Treatment agent for TCF3-HLF type b-cell acute lymphoblastic leukemia

A therapeutic agent targeting interleukin-1β effectively suppresses TCF3-HLF type B-ALL cell proliferation, addressing the lack of effective treatments for this leukemia type.

JP2024165887APending Publication Date: 2024-11-28TOKYO UNIVERSITY OF SCIENCE
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023082464
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Filing Date
2023-05-18
Publication Date
2024-11-28

AI Technical Summary

Technical Problem

There is no effective treatment method for refractory TCF3-HLF type B-cell acute lymphoblastic leukemia (B-ALL).

Method used

A therapeutic agent that inhibits the function and/or expression of interleukin-1β, utilizing components such as anti-interleukin-1β antibodies, interleukin-1 receptor antagonists, low molecular weight compounds, and nucleic acids, is developed to target TCF3-HLF type B-ALL cells.

Benefits of technology

The therapeutic agent significantly suppresses cell proliferation in TCF3-HLF type B-ALL cells, offering potential therapeutic benefits including curing, alleviation, or inhibiting the progression of the leukemia.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024165887000001_ABST
    Figure 2024165887000001_ABST
Patent Text Reader

Abstract

To provide a novel treatment agent for TCF3-HLF type B-cell acute lymphoblastic leukemia (TCF3-HLF type B-ALL).SOLUTION: A treatment agent for TCF3-HLF type B-cell acute lymphoblastic leukemia contains an active ingredient that inhibits the functions and / or expression of interleukin-1β.SELECTED DRAWING: Figure 1
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a therapeutic agent for TCF3-HLF B-cell acute lymphoblastic leukemia. [Background technology]

[0002] Acute lymphoblastic leukemia (ALL) is a type of blood cancer, and is the most frequent malignant tumor that occurs in childhood (Non-Patent Document 1, etc.). Acute lymphocytic leukemia is classified into B-cell lymphocytic leukemia (B-ALL) and T-cell lymphocytic leukemia (T-ALL). Among them, refractory B-ALL is characterized by the expression of TCF3 (Transcription Factor 3) fusion gene, and is classified into TCF3-HLF type B-ALL, TCF3-PBX1 type B-ALL, etc. [Prior art documents] [Non-patent literature]

[0003] [Non-Patent Document 1] Tomokatsu Ikawa, "19. Development of new therapeutic drugs for acute lymphoblastic leukemia," Uehara Memorial Foundation Research Reports, 35 (2021) Summary of the Invention [Problem to be solved by the invention]

[0004] On the other hand, no effective treatment has yet been found for refractory B-ALL. In light of this situation, the present inventors focused on TCF3-HLF B-ALL among refractory B-ALL and searched for an effective therapeutic target.

[0005] The present invention has been made in view of the above circumstances, and an objective of the present invention is to provide a novel therapeutic agent for TCF3-HLF B-cell acute lymphoblastic leukemia (TCF3-HLF B-ALL). [Means for solving the problem]

[0006] The present inventors have discovered interleukin-1β as a novel therapeutic target for TCF3-HLF B-cell acute lymphoblastic leukemia, and have completed the present invention. More specifically, the present invention provides the following.

[0007] (1) A therapeutic agent for TCF3-HLF B-cell acute lymphoblastic leukemia, comprising an active ingredient that inhibits the function and / or expression of interleukin-1β.

[0008] (2) The therapeutic agent according to (1), wherein the active ingredient comprises one or more selected from an anti-interleukin-1β antibody, an interleukin-1 receptor antagonist, a low molecular weight compound, and a nucleic acid.

[0009] (3) The therapeutic agent according to (1) or (2), which is used in combination with a B-cell lymphoma inhibitor. Effect of the Invention

[0010] According to the present invention, a novel therapeutic agent for TCF3-HLF B-cell acute lymphoblastic leukemia (TCF3-HLF B-ALL) is provided. [Brief description of the drawings]

[0011] [Figure 1] FIG. 1 shows the effect of IL-1β expression in TCF3-HLF type B-ALL cells. [Diagram 2] FIG. 1 shows the effect of IL-1β expression in TCF3-HLF type B-ALL cells in the presence of anti-IL-1β antibody. [Diagram 3] FIG. 1 shows the effect of IL-1β expression in TCF3-HLF type B-ALL cells in the presence of an anti-IL-1β antibody and an antileukemia agent. [Figure 4] FIG. 1 shows the effect of IL-1β expression in TCF3-HLF type B-ALL cells in the presence of a low molecular weight compound. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0012] Hereinafter, an embodiment of the present invention will be described, but the present invention is not limited thereto.

[0013] <Therapeutic Agent of the Present Invention> The present invention relates to a therapeutic agent for TCF3-HLF B-cell acute lymphoblastic leukemia. The main technical feature of the therapeutic agent of the present invention is that it contains an active ingredient that inhibits the function and / or expression of interleukin-1β.

[0014] As described in the Examples below, the present inventors established a mouse model that develops TCF3-HLF B-ALL, and attempted to identify the mechanism of onset through genetic analysis. As a result, we found that the differentially expressed genes were significantly different between TCF3-HLF B-ALL cells and TCF3-PBX1 B-ALL cells. They also found that TCF3-HLF B-ALL cells have a unique characteristic of having significantly high expression of interleukin-1β (IL-1β).

[0015] Furthermore, the inventors found that IL-1β promotes the proliferation of TCF3-HLF B-ALL cells, as deletion of the IL-1β gene in TCF3-HLF B-ALL cells significantly suppressed cell proliferation.

[0016] These results indicate that IL-1β is an effective therapeutic target for TCF3-HLF B-ALL. Based on this finding, inhibition of IL-1β function and / or expression is expected to be effective in treating TCF3-HLF B-cell acute lymphoblastic leukemia.

[0017] In the present invention, "treatment" includes cure, alleviation, remission, inhibition of progression, and the like of the symptoms of TCF3-HLF B-cell acute lymphoblastic leukemia. In the present invention, the term "therapeutic agent" includes pharmaceuticals that achieve the above-mentioned therapeutic effects.

[0018] The composition of the therapeutic agent of the present invention will be described in detail below.

[0019] (1) Active ingredient The therapeutic agent of the present invention contains, as an active ingredient, a component that inhibits the function and / or expression of interleukin-1β.

[0020] The component that inhibits the function and / or expression of interleukin-1β may be one type of component or a combination of two or more types of components.

[0021] In the present invention, the term "component that inhibits the function of interleukin-1β" ​​includes components that inhibit any physiological function of interleukin-1β protein. Examples of components that inhibit the function of interleukin-1β include anti-interleukin-1β antibodies, interleukin-1 receptor antagonists, and low molecular weight compounds that inhibit the function of interleukin-1β.

[0022] In the present invention, the term "component that inhibits the expression of interleukin-1β" ​​includes a component that suppresses or blocks the expression of the interleukin-1β gene. Components that inhibit the expression of interleukin-1β include low molecular weight compounds and nucleic acids that suppress or block the expression of the interleukin-1β gene.

[0023] In the present invention, the term "low molecular weight compound" includes pharmaceutical compounds having a molecular weight of 1000 or less. An example of a low molecular weight compound that is effective in the present invention is "ONX-0914" (CAS number: 960374-59-8, molecular weight: 580.70), which is known as an immunoproteasome inhibitor.

[0024] In the present invention, the term "nucleic acid" includes any form of nucleic acid (DNA, mRNA, siRNA, shRNA, antisense oligonucleotide, etc.) that can be used as a nucleic acid medicine.

[0025] The preferred form of the active ingredient in the present invention is one or more selected from an anti-interleukin-1β antibody, an interleukin-1 receptor antagonist, a low molecular weight compound, and a nucleic acid. Among these, an anti-interleukin-1β antibody is particularly preferred from the viewpoint of easily achieving the effects of the present invention.

[0026] (2) Other active ingredients The therapeutic agent of the present invention may or may not contain active ingredients other than those mentioned above, provided that the effects of the present invention are not impaired. Furthermore, the therapeutic agent of the present invention may or may not be used in combination with other active ingredients than those mentioned above, as long as the effects of the present invention are not impaired.

[0027] The therapeutic agent of the present invention can be used in combination with, for example, a conventional therapeutic agent for leukemia. An example of such a leukemia treatment is "venetoclax" (CAS number: 1257044-40-8), which is known as a B-cell lymphoma-2 (BCL-2) inhibitor. As a result of the inventors' studies, it was found that when venetoclax is combined with the therapeutic agent of the present invention (especially, an anti-IL-1β antibody), the proliferation of TCF3-HLF type B-ALL cells can be significantly suppressed compared to administration of the anti-IL-1β antibody alone or administration of venetoclax alone.

[0028] The ratio of the therapeutic agent of the present invention to other active ingredients used is not particularly limited, but may be 143.94:1 to 287.87:1 by mass.

[0029] (3) Other ingredients The therapeutic agent of the present invention may or may not contain any optional ingredient that may be contained in a conventional pharmaceutical product, as long as the effect of the present invention is not impaired. Such ingredients include solvents, excipients, stabilizers, antioxidants, dyes, etc. The types and amounts of these ingredients can be appropriately selected depending on the form of the therapeutic agent of the present invention.

[0030] (4) Form of the therapeutic agent of the present invention The form of the therapeutic agent of the present invention is not particularly limited, and may be an injection, an oral agent, or the like.

[0031] (5) Subjects to whom the therapeutic agent of the present invention is administered The subjects to which the therapeutic agent of the present invention is administered include any living organism that may develop TCF3-HLF B-cell acute lymphoblastic leukemia, for example, humans and non-human mammals.

[0032] (6) Dose of the therapeutic agent of the present invention The dosage of the therapeutic agent of the present invention can be appropriately determined depending on the symptoms and the condition (age, body weight, etc.) of the subject to be administered. EXAMPLES

[0033] The present invention will be described in more detail below with reference to examples, but the present invention is not limited to these examples.

[0034] (1) Generation of TCF3 fusion gene-expressing iLS cells Lineage marker (LSK) in the bone marrow of B6 mice - Sca-1 + ckit + We used a retrovirus to introduce human ID3 and modified estrogen receptor (ERT2) fusion gene (hID3-ERT2) into iLS cells, and then cultured them under conditions that induce B cell differentiation to produce iLS cells (induced leukocyte stem cells). In addition, retrovirus was produced from PLAT-E packaging cells (obtained from Professor Toshio Kitamura, Institute of Medical Science, University of Tokyo) by standard methods. Next, the TCF3-PBX1 gene or the TCF3-HLF gene was introduced into the iLS cells using a retrovirus. Two days after gene transfer, cells positive for human NGFR, a selection marker for gene-transfected cells, were sorted to obtain "TCF3-HLF-positive iLS cells" and "TCF3-PBX1-positive iLS cells" as TCF3 fusion gene-expressing iLS cells.

[0035] The generation of iLS cells was performed based on the method of Ikawa et al. (“Induced Developmental Arrest of Early Hematopoietic Progenitors Leads to the Generation of Leukocyte Stem Cells.”, Stem Cell Reports. 2015 Nov 10;5(5):716-727. doi: 10.1016 / j.stemcr.2015.09.012. PMID: 26607950).

[0036] (2) Carcinogenicity evaluation of TCF3 fusion gene-expressing iLS cells The TCF3 fusion gene-expressing iLS cells obtained above were cultured in the tail vein of irradiated wild-type mice at 2.0 × 10 6 The cells were transplanted one by one. As a result, all of the mice died within 3 to 4 months after transplantation. In these mice, the spleen and lymph nodes were enlarged, and the number of "pro-B cells" (CD19 + B220 + IgM - CD43 + cKit + ) stage, infiltration of "B-ALL-like cells" was confirmed.

[0037] These results confirmed that TCF3 fusion gene-expressing iLS cells induce TCF3-HLF or TCF3-PBX1 type B-ALL in vivo in mice.

[0038] Hereinafter, B-ALL-like cells obtained as a result of transplantation of TCF3-HLF-positive iLS cells will be referred to as "TCF3-HLF type B-ALL cells." Also, B-ALL-like cells obtained as a result of transplantation of TCF3-PBX1-positive iLS cells will be referred to as "TCF3-PBX1 type B-ALL cells."

[0039] (3) Gene expression analysis We performed gene expression analysis on TCF3-HLF and TCF3-PBX1 B-ALL cells, as well as on normal pro-B cells as a control.

[0040] (3-1)PCA analysis Principal component analysis (PCA) revealed that the gene expression patterns of TCF3-HLF B-ALL cells and TCF3-PBX1 B-ALL cells were significantly different.

[0041] (3-2) Pathway analysis Pathway analysis of differentially expressed genes using Metascape (https: / / metascape.org / gp / index.html# / main / step1) revealed increased expression of genes related to lymphocyte activation, cytokine production, inflammatory responses, etc. in TCF3-HLF B-ALL cells. When we analyzed the transcription factors that control the expression of these genes, we found not only factors involved in carcinogenesis (TP53, MYC, etc.) and factors that have been suggested to be related to TCF3-HLF (P300, BCL6, etc.), but also factors involved in inflammatory responses (NFKB1, STAT3, etc.). Furthermore, the expression levels of the above genes in TCF3-HLF B-ALL cells were significantly higher than those in normal pro-B cells and TCF3-PBX1 B-ALL cells.

[0042] (3-3) Quantitative reverse transcription PCR analysis Based on the results of (3-2) above, the expression of each gene was analyzed by quantitative reverse transcription PCR (RT-qPCR). The expression level of IL-1β was particularly high in TCF3-HLF B-ALL cells, and was more than 100-fold higher than that in TCF3-PBX1 B-ALL cells. Based on these results, further investigations were carried out focusing on IL-1β.

[0043] (4)Examination of IL-1β expression in TCF3-HLF type B-ALL cells Cell transplantation into mice was performed in the same manner as described above (2), and mice with TCF3-HLF B-ALL were obtained. We analyzed the expression levels of IL-1β mRNA and protein in cells obtained from mice with pre- and post-onset TCF3-HLF B-ALL by RT-qPCR and Western blotting. As a result, IL-1β expression was not detected in cells before the onset of TCF3-HLF B-ALL. In contrast, significant expression of IL-1β was detected in cells after the onset of TCF3-HLF B-ALL.

[0044] (5) Effect of IL-1β expression in TCF3-HLF type B-ALL cells -1 We investigated the effect of deleting the IL-1β gene in TCF3-HLF type B-ALL cells (YCUB2 cells), which highly express the IL-1β gene. The CRISPR-Cas9 system was used to create IL-1β gene-deficient cells.

[0045] In IL-1β gene-deficient cells, cell proliferation was significantly suppressed compared to the control (TCF3-HLF type B-ALL cells not deficient in the IL-1β gene) (Figure 1, *** p value < 0.001). No increase in apoptotic cells was observed, suggesting that the proliferation rate of apoptotic cells was suppressed. On the other hand, when IL-1β-deficient cells were cultured with recombinant human (rh)IL-1β, cell proliferation was restored in a concentration-dependent manner. These results indicate that IL-1β promotes the proliferation of TCF3-HLF B-ALL cells.

[0046] (6) Effect of IL-1β expression in TCF3-HLF type B-ALL cells - 2 When 50 μg / mL of anti-IL-1β antibody (InvivoGen, #mabg-hil1b-3) was added to TCF3-HLF type B-ALL cells (YCUB2 cells) and cultured for 6 days, cell proliferation was significantly suppressed compared to the control (no antibody added) (Figure 2, *** p-value<0.001).

[0047] (7) Effect of IL-1β expression in TCF3-HLF type B-ALL cells - 3 Addition of 300 nM venetoclax together with 50 μg / mL anti-IL-1β antibody to TCF3-HLF type B-ALL cells (YCUB2 cells) significantly suppressed cell proliferation (Figure 3, * p-value < 0.05, ** (p value < 0.01). Venetoclax is a B-cell lymphoma-2 (BCL-2) inhibitor known for treating leukemia. This inhibitory effect was significant not only relative to the control (no antibody added), but also relative to administration of anti-IL-1β antibody alone and administration of venetoclax alone.

[0048] (8)Effect of IL-1β expression in TCF3-HLF type B-ALL cells-4 Cell transplantation was performed in mice in the same manner as in (2) above, and mice with TCF3-HLF B-ALL were obtained. These mice were intravenously administered 15 mg / kg of ONX-0914 per day for 10 days. ONX-0914 (CAS number: 960374-59-8) is a small molecule compound known as an immunoproteasome inhibitor. As a result, mice administered ONX-0914 had a significantly longer survival time than controls (not administered ONX-0914).

[0049] Based on these results, quantitative reverse transcription PCR analysis was performed on TCF3-HLF B-ALL cells cultured with the addition of ONX-0914, and the expression level of IL-1β was significantly lower than that of the control (without the addition of ONX-0914) (Figure 4, *** p-value<0.001). Thus, ONX-0914 inhibits IL-1β expression and was found to be useful in the treatment of TCF3-HLF B-ALL.

[0050] (9) Conclusion First, we found that IL-1β expression was significantly higher in TCF3-HLF B-ALL cells, and further found that IL-1β promoted the proliferation of TCF3-HLF B-ALL cells. They then confirmed that the addition of anti-IL-1β antibody or ONX-0914 to TCF3-HLF type B-ALL cells suppressed cell proliferation. Therefore, IL-1β is a novel therapeutic target for TCF3-HLF B-ALL, and therefore compounds that inhibit the function of IL-1β (anti-IL-1β antibodies, IL-1 receptor antagonists, etc.) and compounds that inhibit the expression of IL-1β (low molecular weight compounds such as ONX-0914, nucleic acids, etc.) can be effective therapeutic agents for TCF3-HLF B-ALL.

[0051] Furthermore, the effect of suppressing cell proliferation can be further enhanced by combining an anti-IL-1β antibody with a conventionally known leukemia treatment such as a B-cell lymphoma inhibitor (e.g., venetoclax).

Claims

1. A therapeutic agent for TCF3-HLF type B-cell acute lymphoblastic leukemia, comprising an active ingredient that inhibits the function and / or expression of interleukin-1β.

2. The therapeutic agent according to claim 1, wherein the active ingredient comprises one or more selected from an anti-interleukin-1β antibody, an interleukin-1 receptor antagonist, a low molecular weight compound, and a nucleic acid.

3. The therapeutic agent according to claim 1 or 2, which is used in combination with a B-cell lymphoma inhibitor.